Abstract

Genetic testing provides valuable insights into family screening strategies, diagnosis, and prognosis in patients with hypertrophic cardiomyopathy (HCM). On the other hand, genetic testing carries socio-economical and psychological burdens. It is therefore important to identify patients with HCM who are more likely to have positive genotype. However, conventional prediction models based on clinical and echocardiographic parameters offer only modest accuracy and are subject to intra- and inter-observer variability. We therefore hypothesized that deep convolutional neural network (DCNN, a type of deep learning) analysis of echocardiographic images improves the predictive accuracy of positive genotype in patients with HCM. In each case, we obtained parasternal short- and long-axis as well as apical 2-, 3-, 4-, and 5-chamber views. We employed DCNN algorithm to predict positive genotype based on the input echocardiographic images. We performed 5-fold cross-validations. We used 2 reference models—the Mayo HCM Genotype Predictor score (Mayo score) and the Toronto HCM Genotype score (Toronto score). We compared the area under the receiver-operating-characteristic curve (AUC) between a combined model using the reference model plus DCNN-derived probability and the reference model. We calculated the p-value by performing 1,000 bootstrapping. We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). In addition, we examined the net reclassification improvement. We included 99 adults with HCM who underwent genetic testing. Overall, 45 patients (45%) had positive genotype. The new model combining Mayo score and DCNN-derived probability significantly outperformed Mayo score (AUC 0.86 [95% CI 0.79–0.93] vs. 0.72 [0.61–0.82]; p < 0.001). Similarly, the new model combining Toronto score and DCNN-derived probability exhibited a higher AUC compared to Toronto score alone (AUC 0.84 [0.76–0.92] vs. 0.75 [0.65–0.85]; p = 0.03). An improvement in the sensitivity, specificity, PPV, and NPV was also achieved, along with significant net reclassification improvement. In conclusion, compared to the conventional models, our new model combining the conventional and DCNN-derived models demonstrated superior accuracy to predict positive genotype in patients with HCM.

Highlights

  • Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, affecting ∼1 in 200–500 people [1]

  • The inferences from our study suggest that echocardiographic parameters related to the left atrium—e.g., left atrial diameter, volume, and ejection fraction—have a potential to predict positive genotype in the HCM population

  • For patients and treating physicians, the novel deep learning-based method introduced in the present study can be used as an assistive technology to inform the decision-making process of performing genetic testing; deep learning coupled to human expertise can provide more accurate pre-test probability

Read more

Summary

Introduction

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, affecting ∼1 in 200–500 people [1]. Investigators have documented dozens of genes and >1,000 gene mutations associated with HCM pathogenesis [2]. Genetic testing has become a powerful tool for family screening, diagnosis, and prognostication in HCM [3, 4]. Genetic testing can determine whether each of the first-degree relatives is at risk of developing HCM [3, 5]. Genetic testing can help clinicians establish the diagnosis of HCM in patients with atypical clinical features [5]. It is important to precisely determine the pretest probability in each patient with HCM prior to performing genetic testing

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call